New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
Gilead Sciences Exercises Option to License Assembly Biosciences' Helicase-Primase Inhibitor Programs for Recurrent Genital Herpes
Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-2 Trial
Yescarta® Delivers Consistent Safety, Efficacy, and Quality of Life Benefits Across Broad Range of Relapsed/Refractory Large B-cell Lymphoma Patients in New Analysis at ASH 2025
Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma
Kite's Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Gilead's Investigational Single-Tablet Regimen of Bictegravir and Lenacapavir for HIV-1 Treatment Meets Primary Endpoint in Phase 3 ARTISTRY-1 Trial
Gilead's Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis , Offering Alkaline Phosphatase Reduction, Itch Relief and Potential to Slow Disease Progression
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
